Reference

Study period

Inclusion

criteria

No. of S. aureus

No. of

MRSA (%)

MRSA clone

[12]

2004-2009

Hospitalized patients’ skin and soft tissue samples had cultures obtained (Martinique)

Data not

reported

69

Martinique

CC8-MRSA-IV “Lyone” (50.7%)

CC8-MRSA-IV “UK-EMRSA” (7.2%)

ST8-MRSA-IV “USA300” (7.2%)

ST8-MRSA-IV ACME− (1.45%)

WA-MRSA-62 PVL− (1.45%)

ST239-MRSA-III “Brazillian” (1.45%)

ST72-MRSA-IV “USA700” (1.45%)

CC59 ST59-MRSA-V (1.45%)

CC5 ST5-MRSA-I “Geraldine” (13%)

CC5-MRSA-IV “pediatric” (4.3%)

CC5-MRSA-IV “pediatric” PVL− (1.45%)

CC80-MRSA-IV PVL− “European CA-MRSA” (10%)

Jamaica

ST8-MRSA-IV “USA300” (6.25%)

ST5/ST225-MRSA-II New York-Japan (12.5%)

Trinidad

ST8-MRSA-IV “USA300” (6.25%)

ST239-MRSA-III “Brazillian” (18.75%)

CC5-MRSA-IV “pediatric” (6.25%)

Tobago

ST8-MRSA-IV “USA300” (12.5%)

ST239-MRSA-III “Brazillian” (12.5%)

WA-MRSA-62 PVL− (6.25%)

Guadeloupe

ST8-MRSA-IV “USA300” (6.25%)

WA-MRSA-62 PVL− (6.25%)

CC5 ST5-MRSA-I “Geraldine” (6.25)

2010-2011

Hospitalized patients’ skin and soft tissue samples had cultures obtained (Trinidad, Tobago, Jamaica, Guadeloupe)

Data not

reported

16

[11]

2014-2015

Hospitalized patients’ blood, bone, ear, fluids, surgical drains, tissue, urine and wounds had culture obtained

Data not

reported

100

CA-MRSA PVL+ (76%)

CA-MRSA PVL− (14%)

HA-MRSA, PVL+ (9%)

HA-MRSA, PVL− (1%)

CA-MRSA, PVL+ (95.9%)

CA-MRSA, spa+, mecA+ (4.1%)

CA-MRSA, spa+, mecA+ resistant to vancomycin (2.07%)

2013-2016

Outpatients’ convenience samples from wounds, nasal, penile and vaginal

had culture obtained

Data not

reported

193

[19]

2008

Hospitalized patients’ surgical wounds, bronchial/tracheal aspirations, blood, skin, abdominal drainage and chest tissue biopsy had culture obtained

68

40 (58.9)

Spa-types

t149 (60%)

CC8 t008 (20%), PVL+

t037 (15%),

t4088 (2.5)

t2029 (2.5%)